par Giaj Levra, Niccolo;Giaj Levra, Matteo;Durieux, Valérie 
;Novello, Silvia;Besse, Benjamin;Hasan, Baktiar;HENDRIKS, Lizza;LEVY, Antonin;Dingemans, Anne-Marie C;Berghmans, Thierry ;European Organization for Research and Treatment of Cancer-Lung Cancer Group,
Référence Journal of Thoracic Oncology, 14, 12, page (2053-2061)
Publication Publié, 2019-12-01
;Novello, Silvia;Besse, Benjamin;Hasan, Baktiar;HENDRIKS, Lizza;LEVY, Antonin;Dingemans, Anne-Marie C;Berghmans, Thierry ;European Organization for Research and Treatment of Cancer-Lung Cancer Group, Référence Journal of Thoracic Oncology, 14, 12, page (2053-2061)
Publication Publié, 2019-12-01
Article révisé par les pairs
| Résumé : | Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC. |
